Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093119 · ClinicalTrials.gov registry record · Phase 2
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00093119 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 75 participants.
The verdict
NCT00093119, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This trial will treat patients previously treated for advanced (metastatic) melanoma (skin cancer) with a new chemotherapeutic medicine. The new chemotherapy will be administered weekly in cycles of three weekly doses followed by one week rest. A minimum of three cycles of therapy will be given to determine the anti-tumor response of the new chemotherapy. Patients may continue to stay on therapy a maximum of 9-12 cycles if treatment shows continuing benefit.
Interventions
- DRUG ABI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2003-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093119
The ClinicalTrials.gov registry entry for NCT00093119 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABI-007 is the first listed.
NCT00093119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093119 about?
NCT00093119 is a clinical study titled "Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma". This trial will treat patients previously treated for advanced (metastatic) melanoma (skin cancer) with a new chemotherapeutic medicine. The new chemotherapy will be administered weekly in cycles of three weekly doses followed by one week rest. A minimum of three cycles of therapy will be given to d...
What is the current status of trial NCT00093119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2003-07.
What interventions are being tested in trial NCT00093119?
The interventions under investigation include: ABI-007 (DRUG).
Who is sponsoring clinical trial NCT00093119?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.